FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090016030> ?p ?o ?g. }

• W2090016030 endingPage "367" @default.
• W2090016030 startingPage "360" @default.
• W2090016030 abstract "Patients with malignant ovarian (n = 111) and borderline (n = 8) tumors (FIGO stage III/IV) underwent surgery and chemotherapy and were analyzed clinically (age, residual tumor after surgery) and morphologically (type, grade, psammoma body content), and by means of flow cytometry (DNA ploidy, S-phase fraction). Follow-up was 12-72 months for investigation of survival. Patients under 60 years of age (n = 18) with malignant tumors showed longer survival than patients over 60 (n = 93) (P = 0.078). Residual tumor was relevant for prognosis in malignant tumors only if macroscopically there was no residual disease (n = 13). There were no significant differences between residual tumors less than or equal to 2 cm (n = 61) and greater than 2 cm (n = 37). WHO typing was of little importance for survival analysis. Compared to borderline tumors (n = 8), serous (n = 65), endometrioid (n = 13), nonclassifiable (n = 12), mucinous carcinomas (n = 8), and nonepithelial tumors (n = 12) had a poor prognosis. Psammoma bodies were found in 25 patients with serous carcinomas, 7 of them had a high content. The prognosis for these 7 patients was much better than that for patients with a moderate or low psammoma body content (P = 0.006). Twenty-three epithelial tumors were graded G1, 28 were G2, and 47 were G3. However, grading was considered only as a prognostic factor in serous carcinomas (n = 65) (P = 0.028). A total of 199 DNA histograms from 119 patients were analyzed by flow cytometry (FCM). There were no correlations between tumor type and DNA ploidy or S-phase fraction. Seven of eight borderline tumor and all serous carcinomas with a high content of psammoma bodies were diploid combined with a low (less than or equal to 4%) S-phase fraction. DNA ploidy and S-phase fraction were excellent prognosticators. Of 99 epithelial malignant tumors, 35 were diploid and 64 were aneuploid. An S-phase fraction less than or equal to 4% was found in 39 patients, 4.1-10% in 73 patients, and greater than 10% in 23 patients. Diploid tumors and tumors with a low S-phase fraction showed the best survival (P = 0.007, resp. 0.0001). Our study emphasizes the importance of an accurate histology, including information on psammoma body content, and the importance of DNA flow cytometry. The advantage of FCM is that the results are simple, reproducible, and objective." @default.
• W2090016030 created "2016-06-24" @default.
• W2090016030 creator A5015679483 @default.
• W2090016030 creator A5035387502 @default.
• W2090016030 creator A5045630585 @default.
• W2090016030 creator A5054580261 @default.
• W2090016030 creator A5062296689 @default.
• W2090016030 creator A5075139949 @default.
• W2090016030 date "1989-06-01" @default.
• W2090016030 modified "2023-10-12" @default.
• W2090016030 title "DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors" @default.
• W2090016030 cites W1969702600 @default.
• W2090016030 cites W1976926107 @default.
• W2090016030 cites W1977349128 @default.
• W2090016030 cites W1984753816 @default.
• W2090016030 cites W1988971154 @default.
• W2090016030 cites W1998414112 @default.
• W2090016030 cites W1999189627 @default.
• W2090016030 cites W2004918295 @default.
• W2090016030 cites W2018708063 @default.
• W2090016030 cites W2022395211 @default.
• W2090016030 cites W2028548773 @default.
• W2090016030 cites W2029339535 @default.
• W2090016030 cites W2029857241 @default.
• W2090016030 cites W2033929602 @default.
• W2090016030 cites W2035602919 @default.
• W2090016030 cites W2041790586 @default.
• W2090016030 cites W2048378235 @default.
• W2090016030 cites W2055107192 @default.
• W2090016030 cites W2055793472 @default.
• W2090016030 cites W2056434756 @default.
• W2090016030 cites W2068340072 @default.
• W2090016030 cites W2082617319 @default.
• W2090016030 cites W2082978636 @default.
• W2090016030 cites W2092513942 @default.
• W2090016030 cites W2313357390 @default.
• W2090016030 cites W2369006184 @default.
• W2090016030 cites W2412874053 @default.
• W2090016030 cites W2461171695 @default.
• W2090016030 cites W2467831734 @default.
• W2090016030 cites W3041047318 @default.
• W2090016030 doi "https://doi.org/10.1016/0090-8258(89)90528-3" @default.
• W2090016030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2722063" @default.
• W2090016030 hasPublicationYear "1989" @default.
• W2090016030 type Work @default.
• W2090016030 sameAs 2090016030 @default.
• W2090016030 citedByCount "46" @default.
• W2090016030 countsByYear W20900160302013 @default.
• W2090016030 countsByYear W20900160302016 @default.
• W2090016030 crossrefType "journal-article" @default.
• W2090016030 hasAuthorship W2090016030A5015679483 @default.
• W2090016030 hasAuthorship W2090016030A5035387502 @default.
• W2090016030 hasAuthorship W2090016030A5045630585 @default.
• W2090016030 hasAuthorship W2090016030A5054580261 @default.
• W2090016030 hasAuthorship W2090016030A5062296689 @default.
• W2090016030 hasAuthorship W2090016030A5075139949 @default.
• W2090016030 hasConcept C121608353 @default.
• W2090016030 hasConcept C126322002 @default.
• W2090016030 hasConcept C142724271 @default.
• W2090016030 hasConcept C143998085 @default.
• W2090016030 hasConcept C146357865 @default.
• W2090016030 hasConcept C150173356 @default.
• W2090016030 hasConcept C151730666 @default.
• W2090016030 hasConcept C174865614 @default.
• W2090016030 hasConcept C18903297 @default.
• W2090016030 hasConcept C203014093 @default.
• W2090016030 hasConcept C204232928 @default.
• W2090016030 hasConcept C2777286243 @default.
• W2090016030 hasConcept C2780427987 @default.
• W2090016030 hasConcept C553184892 @default.
• W2090016030 hasConcept C71924100 @default.
• W2090016030 hasConcept C86803240 @default.
• W2090016030 hasConcept C90924648 @default.
• W2090016030 hasConceptScore W2090016030C121608353 @default.
• W2090016030 hasConceptScore W2090016030C126322002 @default.
• W2090016030 hasConceptScore W2090016030C142724271 @default.
• W2090016030 hasConceptScore W2090016030C143998085 @default.
• W2090016030 hasConceptScore W2090016030C146357865 @default.
• W2090016030 hasConceptScore W2090016030C150173356 @default.
• W2090016030 hasConceptScore W2090016030C151730666 @default.
• W2090016030 hasConceptScore W2090016030C174865614 @default.
• W2090016030 hasConceptScore W2090016030C18903297 @default.
• W2090016030 hasConceptScore W2090016030C203014093 @default.
• W2090016030 hasConceptScore W2090016030C204232928 @default.
• W2090016030 hasConceptScore W2090016030C2777286243 @default.
• W2090016030 hasConceptScore W2090016030C2780427987 @default.
• W2090016030 hasConceptScore W2090016030C553184892 @default.
• W2090016030 hasConceptScore W2090016030C71924100 @default.
• W2090016030 hasConceptScore W2090016030C86803240 @default.
• W2090016030 hasConceptScore W2090016030C90924648 @default.
• W2090016030 hasIssue "3" @default.
• W2090016030 hasLocation W20900160301 @default.
• W2090016030 hasLocation W20900160302 @default.
• W2090016030 hasOpenAccess W2090016030 @default.
• W2090016030 hasPrimaryLocation W20900160301 @default.
• W2090016030 hasRelatedWork W1963941278 @default.
• W2090016030 hasRelatedWork W2036060509 @default.
• W2090016030 hasRelatedWork W2054579795 @default.

• next